---
document_datetime: 2024-09-24 15:42:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/xalkori-epar-all-authorised-presentations_en.pdf
document_name: xalkori-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.2063713
conversion_datetime: 2025-12-25 12:45:09.578017
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form              | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|----------------------------------|---------------------------|-----------------------|-------------|
| EU/1/12/793/001  | XALKORI           | 200 mg     | Capsule, hard                    | Oral use                  | Blister (PVC/alu)     | 60 capsules |
| EU/1/12/793/002  | XALKORI           | 200 mg     | Capsule, hard                    | Oral use                  | Bottle (HDPE)         | 60 capsules |
| EU/1/12/793/003  | XALKORI           | 250 mg     | Capsule, hard                    | Oral use                  | Blister (PVC/alu)     | 60 capsules |
| EU/1/12/793/004  | XALKORI           | 250 mg     | Capsule, hard                    | Oral use                  | Bottle (HDPE)         | 60 capsules |
| EU/1/12/793/005  | XALKORI           | 20 mg      | Granules in capsules for opening | Oral use                  | Bottle (HDPE)         | 60 capsules |
| EU/1/12/793/006  | XALKORI           | 50 mg      | Granules in capsules for opening | Oral use                  | Bottle (HDPE)         | 60 capsules |
| EU/1/12/793/007  | XALKORI           | 150 mg     | Granules in capsules for opening | Oral use                  | Bottle (HDPE)         | 60 capsules |